Picoprep® – a clearing agent with a new dosing schedule
Authors:
M. Lukáš
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha
Published in:
Gastroent Hepatol 2017; 71(2): 175-176
Category:
Drug Profile
doi:
https://doi.org/10.14735/amgh2017175
Sources
1. Katz PO, Rex DK, Epstein M et al. A dual-action, low-volume bowel cleanser administered the day before colonoscopy: results from the SEE CLEAR II study. Am J Gastroenterol 2013; 108 (3): 401–409.
2. Souhrn údajů o přípravku: Příloha č. 2 k rozhodnutí o změně registrace sp. zn. sukls176730/201.
3. Kiesslich R, Schubert S, Mross M et al. Efficacy and safety of Picoprep tailored dosing compared with Picoprep day-before dosing for colon cleansing: a multi-centric, randomised study. Endosc Int Open 2017; 05 (04): E282–E290. doi: 10.1055/s-0043-102433.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2017 Issue 2
Most read in this issue
- Ustekinumab – a new biological therapy for patients with Crohn’s disease
- Picoprep® – a clearing agent with a new dosing schedule
- Czech Society of Hepatology guidelines for diagnosis and treatment of acute porphyrias
- Treatment of bleeding caused by liver cirrhosis-associated portal hypertension – update of Czech Society of Hepatology guidelines